These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 23481458

  • 61. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.
    Unniachan S, Bash LD, Khovidhunkit W, Sri RZ, Vicaldo E, Recto C, Ambegaonkar BM.
    Int J Clin Pract; 2014 Aug; 68(8):1010-9. PubMed ID: 24666791
    [Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Aug; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 64. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
    Hsu TY, Chirovsky D, Moy FM, Ambegaonkar BM.
    Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA, Egger A.
    J Manag Care Pharm; 2006 Apr; 12(9):745-51. PubMed ID: 17249907
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
    Hsu TY, Chirovsky D, Moy FM, Ambegaonkar BM.
    Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 72. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 73. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
    Hsu TY, Chirovsky D, Moy FM, Ambegaonkar BM.
    Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
    [Abstract] [Full Text] [Related]

  • 74. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Apr; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [New Search]
    of 4.